Scientists' new achievements in cancer recurrence research!

-5) Cancer Res: Leukemia drug dasatini or promising treatment for special relapse T-cell lymphoma doi:10.1158/0008-5472.CAN-In a study published in the international journal Lancer Research 19-2787, scientists from Tsukiba University in Japan and other institutions found that T-cell lymphoma (AITL, angioimmunoblastic T-cell mphoma) in blood vessel immune mother cells may rely on T-cellular sensor signals. The drug dasatinib, which targets the TCR (T-cellular subject) path path, improves mouse models and the prognostication of treatment for clinical patients who have relapsed or are ineffective in conventional therapies, so dasatini is expected to be a new drug candidate for AITL treatment.
AITL is a difficult-to-treat non-Hodgkin's lymphoma, and in this study, the researchers found that in experimental mouse bodies, specific gene mutations that trigger ALTL-like lymphoma may activate T-cellular ligation (TCR) signals, a drug used to treat multiple leukemias, or a drug that can effectively treat recurring or resusciable AITL.
lymphoma is a group of related cancers that affect the body's lymphatic system, usually classified as B-cell lymphoma and T-cell lymphoma according to the type of white blood cell affected, AITL is a rare and malignant T-cell lymphoma with a five-year survival rate of less than 30%; Patients with L often experience symptoms such as fever, rash, and immune activation, and many patients have special genetic changes, such as the DNMT3A, TET2, IDH2, and RhoA genes, which researchers do not yet know play a key role in the development of the disease.
Photo Source: CC0 Public Domain 6 Cell Rep: Developing a new method to effectively inhibit breast cancer recurrence Doi:10.1016/j.celrep.2019.09.032, an international journal In a study in Cell Reports, scientists from Duke University and others found that a new treatment for malignant breast cancer could shut down the growth of cancer cells that are resistant to standard hormone therapy, finding that researchers identified weaknesses in almost all estrogen-positive breast cancers that are resistant to current treatments.
researcher Dr Donald McDonnell said that for breast cancer, the problem of regeneration may cause cancer cells to develop some tolerance to therapy; we hope to reverse or block the drug resistance process for breast cancer, which slowly reveals weaknesses as tumors begin to develop resistance to therapy so that we can target them to inhibit or even kill breast cancer cells. In the
paper, researchers analyzed cellular and mouse models of estrogen-positive breast cancer, which account for about 80 percent of all breast cancers, and identified a common path through which tumor cells could be used to fight off tamine and aromatase inhibitors.
Using pharmacological and biochemical methods, researchers were able to inhibit the activation of this pathline and block the growth of relapsed breast tumors in mice;
7 (Xinhua) -- Chinese and American scientists have teamed up to reveal the mystery of the recurrence of drug-resistant leukemia caused by chemotherapy doi:10.1182/blood.2019002220 Chemotherapy has made the most common childhood cancer ---a acute lymphoblastic leukemia (ALL) --- one of the most curable cancers, but scientists have evidence that the treatment may also cause some patients to relapse.
study, researchers from China and the United States reported that mutations caused by treatment caused by treatment caused resistance in some patients with ALL recurrence.
findings were recently published in the journal Blod.
researchers say our study sheds light on the evolutionary dynamics of ALL in children, which for the first time suggest that chemotherapy drugs, especially thiopental drugs, can cause mutations that cause patients to develop resistance.
" thiopental drugs are a class of drugs used in most ALL treatment stages.
study involved 103 young ALL recurrence patients.
most patients relapse nine months or more after diagnosis.
analysis showed that about 20 percent of these patients had treatment-related mutations at the time of recurrence, some of which were related to drug resistance.
Zhang said: "These mutation characteristics are specific and are related to treatment because they are present only in the genomes of relapsed ALL patients and not in the genomes of other childhood or adult cancers.
: Ebio Media: A new type of fluorescent particle is expected to help diagnose brain cancer and monitor the recurrence of the disease in patients Doi:10.1016/j.ebiom.2019.09 In a recent study published in the international journal Ebio Mediaine, scientists from Massachusetts General Hospital said a chemical that improves brain cancer surgery by fluorescence of tumor cells may help clinicians safely diagnose diseases and monitor patients' responses to the chemical.
Brain cancer is very difficult to diagnose, and patients often have difficulty monitoring after treatment because methods such as tissue biopsies and radiotherapy can damage a patient's brain tissue, and in this study, researchers developed a less invasive alternative that allows patients to ingest a specific substance before brain cancer surgery that turns tumors in the patient's brain bright pink.
the substance is 5-aminoacetylaric acid (5-ALA), an FDA-approved fluorescent preparation that is often used in surgical treatments in suspected brain cancer patients.
for a variety of reasons, the brain absorbs 5-ALA, which normal brain cells do not, because all cells release a particle called an extracellular vesicles, so the researchers To find out if EVs in the blood of patients with post-5-ALA brain cancer will turn fluorescent pink (like a brain tumor), if so, a 5-ALA-based blood test may hopefully diagnose the patient's brain tumor and monitor the recurrence of the patient's cancer.
-9- Nat Immunol: New blood tests or doi:10.1038/s4159 to help predict the risk of disease recurrence in breast cancer patients 0-019-0429-7 In a recent study published in the international journal Nature Immunology, scientists from the City of Hope Comprehensive Cancer Research Center in the United States developed a special blood test that may help predict whether newly diagnosed breast cancer patients will return to the disease in a few years.
P. Lee, M.D., points out that this.